Literature DB >> 10801051

Apolipoprotein E polymorphism and serum concentrations in patients with glycogen storage disease type Ia.

P Trioche1, J Francoual, L Capel, M Odièvre, A Lindenbaum, P Labrune.   

Abstract

In patients with glycogen storage disease type Ia (glucose-6-phosphatase deficiency), serum triglyceride concentrations are markedly raised, whereas phospholipids and cholesterol levels are only moderately elevated. In addition, both VLDL and LDL lipoprotein fractions are raised. Despite these abnormalities, endothelial vascular dysfunction and atherosclerosis seem to be rare in such patients. In view of the crucial role of apolipoprotein E (apoE) in lipid metabolism, we studied both apoE polymorphism (40 patients) and serum concentration (20 patients) in patients with glycogen storage disease type Ia. The distribution of each allele at the apoE locus was similar to that reported in the general population, whereas serum apoE concentrations were raised in our patients. Raised apoE levels in the serum could play an important role in counterbalancing the at-risk-for-atherosclerosis lipid profile of patients with glycogen storage disease type Ia. Moreover, E3 and E4 polymorphisms, predominant in our patients, have a high triglyceride binding capacity and are thus able to increase triglyceride clearance. However, the origin of raised concentrations of apoE is not completely clear though, bearing in mind previous reports regarding serum protein concentrations in such patients, increased hepatic synthesis is likely.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10801051     DOI: 10.1023/a:1005605513534

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  19 in total

Review 1.  Pathophysiology and dietary treatment of the glycogen storage diseases.

Authors:  S W Moses
Journal:  J Pediatr Gastroenterol Nutr       Date:  1990-08       Impact factor: 2.839

2.  Moyamoya disease in a child with glycogen storage disease type Ia.

Authors:  F Goutières; M Bourgeois; P Trioche; J F Demelier; M Odievre; P Labrune
Journal:  Neuropediatrics       Date:  1997-04       Impact factor: 1.947

3.  Blood lipids and rheological modifications in glycogen storage disease.

Authors:  K Keddad; S M Razavian; C Baussan; J Chalas; A Abella; J Levenson; A Simon; N Moatti; A Legrand
Journal:  Clin Biochem       Date:  1996-02       Impact factor: 3.281

4.  Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study.

Authors:  M Vincent-Viry; F Schiele; R Gueguen; K Bohnet; S Visvikis; G Siest
Journal:  Clin Chem       Date:  1998-05       Impact factor: 8.327

Review 5.  Glycogen storage disease in adults.

Authors:  G M Talente; R A Coleman; C Alter; L Baker; B I Brown; R A Cannon; Y T Chen; J F Crigler; P Ferreira; J C Haworth; G E Herman; R M Issenman; J P Keating; R Linde; T F Roe; B Senior; J I Wolfsdorf
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

6.  Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease.

Authors:  H L Greene; L L Swift; H R Knapp
Journal:  J Pediatr       Date:  1991-09       Impact factor: 4.406

7.  Circulating lipids and lipoproteins in glycogen storage disease type I with nocturnal intragastric feeding.

Authors:  E Levy; L A Thibault; C C Roy; M Bendayan; G Lepage; J Letarte
Journal:  J Lipid Res       Date:  1988-02       Impact factor: 5.922

8.  Genetic basis of glycogen storage disease type 1a: prevalent mutations at the glucose-6-phosphatase locus.

Authors:  K J Lei; Y T Chen; H Chen; L J Wong; J L Liu; A McConkie-Rosell; J L Van Hove; H C Ou; N J Yeh; L Y Pan
Journal:  Am J Hum Genet       Date:  1995-10       Impact factor: 11.025

9.  Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a.

Authors:  P J Lee; D S Celermajer; J Robinson; S N McCarthy; D J Betteridge; J V Leonard
Journal:  Atherosclerosis       Date:  1994-09-30       Impact factor: 5.162

Review 10.  Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.

Authors:  P de Knijff; A M van den Maagdenberg; R R Frants; L M Havekes
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

View more
  4 in total

Review 1.  Glycogen metabolism and glycogen storage disorders.

Authors:  Shibani Kanungo; Kimberly Wells; Taylor Tribett; Areeg El-Gharbawy
Journal:  Ann Transl Med       Date:  2018-12

Review 2.  Glycogen storage diseases: new perspectives.

Authors:  Hasan Ozen
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

3.  Decreased plasma concentration of von Willebrand factor antigen (VWF:Ag) in patients with glycogen storage disease type Ia.

Authors:  C Mühlhausen; R Schneppenheim; U Budde; M Merkel; N Muschol; K Ullrich; R Santer
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.750

4.  Continuous glucose monitoring in the treatment of obesity in patients with glycogen storage disease type Ia.

Authors:  Betty Korljan Jelaska; Sanja Baršić Ostojić; Nina Berović; Višnja Kokić
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-12-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.